Formulation and Engineering of Biomaterials
Bioprocessing of bacteriophages via rapid drying onto microcrystals
Article first published online: 2 NOV 2011
DOI: 10.1002/btpr.740
Copyright © 2011 American Institute of Chemical Engineers (AIChE)
Additional Information
How to Cite
Alvarez-Gonzalez, E., Alfadhel, M., Mane, P., Ford, S. J., Moore, B. D. and van der Walle, C. F. (2012), Bioprocessing of bacteriophages via rapid drying onto microcrystals. Biotechnol Progress, 28: 540–548. doi: 10.1002/btpr.740
Publication History
- Issue published online: 10 APR 2012
- Article first published online: 2 NOV 2011
- Accepted manuscript online: 14 OCT 2011 02:07PM EST
- Manuscript Revised: 13 SEP 2011
- Manuscript Received: 10 AUG 2011
Funded by
- BBSRC Bioprocessing Research Industry Club. Grant Number: BB/F004664/1
- Abstract
- Article
- References
- Cited By
Keywords:
- bacteriophages;
- immobilization;
- Staphylococcus aureus;
- bioprocessing;
- protein-coated microcrystals
Abstract
We present an alternative bioprocess for bacteriophages involving room temperature coprecipitation of an aqueous mixture of phage (Siphoviridae) and a crystallizable carrier (glutamine or glycine) in excess of water miscible organic solvent (isopropanol or isobutanol). The resultant suspension of phage-coated microcrystals can be harvested by filtration and the residual solvent removed rapidly by air-drying at a relative humidity of 75%. Albumin or trehalose added at 5% w/w of the crystalline carrier provide for better stabilization of the phage during co-precipitation. Free-flowing dry powders generated from an aqueous solution of phage (∼13 log10 pfu/mL) can be reconstituted in the same aqueous volume to a phage titer of almost 10 log10 pfu/mL; high enough to permit subsequent formulation steps following bioprocessing. The phage-coated microcrystals remain partially stable at room temperature for at least one month, which compares favorably with phage immobilized into polyester microcarriers or lyophilized with excipient (1–5% polyethylene glycol 6000 or 0.1–0.5 M sucrose). We anticipate that this bioprocessing technique will have application to other phage families as required for the development of phage therapies. © 2011 American Institute of Chemical Engineers Biotechnol. Prog., 2012

1520-6033/asset/BTPR_left.gif?v=1&s=a5be2ff5a0fe6ccdaad74a6d128c142e5f71a8da)
1520-6033/asset/BTPR_right.gif?v=1&s=992d113a3e61fc9d3571812359165df86cf830e4)
